Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast

No abstract is available for this paper.

• Publication year

  2024

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2024-08-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-024-07466-9PMID 39180593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy.

  2022cited by this paper
• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

  2021influential reference
• Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis

  2021influential reference
• Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis

  2021influential reference
• Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ

  2020cited by this paper
• Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial

  2020cited by this paper
• Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy

  2020cited by this paper
• Prognostic role of immune infiltrates in breast ductal carcinoma in situ

  2019cited by this paper
• Ductal carcinoma in situ of breast: update 2019.

  2019cited by this paper
• Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial.

  2019cited by this paper
• Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS)

  2019cited by this paper
• Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

  2018cited by this paper
• Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ

  2018cited by this paper
• Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features

  2017cited by this paper
• Breast cancer statistics, 2017, racial disparity in mortality by state

  2017cited by this paper
• Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.

  2017cited by this paper
• Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials

  2017cited by this paper
• Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?

  2016cited by this paper
• The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast

  2016cited by this paper
• The immune microenvironment of breast ductal carcinoma in situ

  2016cited by this paper
• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

  2015cited by this paper
• Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.

  2015cited by this paper
• A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast

  2013cited by this paper
• Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis

  2011cited by this paper
• Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer.

  2008cited by this paper
• Outcome of Patients With Ductal Carcinoma In Situ Untreated After Diagnostic Biopsy: Results From the Nurses' Health Study

  2006influential reference
• The natural history of ductal carcinoma in situ of the breast: a review

  2006cited by this paper
• Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy

  2005cited by this paper

• The predictive value of HER2DX assay with pathological response and prognosis in patients with early HER2-positive breast cancers: commentary on the PHERGain trial

  2025cites this paper
• DCIS Progression and the Tumor Microenvironment: Molecular Insights and Prognostic Challenges

  2025cites this paper
• Tumor‐Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers: Overlooked Potential and Unexplored Frontiers

  2025cites this paper
• Interpretable Machine Learning for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer Using the Baseline Clinical and Pathological Characteristics

  2025cites this paper
• Invasion prediction with artificial intelligence in ductal carcinoma in situ (DCIS) patients: a proof-of-concept study

  2025influential citation
• Tumor-infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast: Correspondence

  2024cites this paper